Objective: Genetic variants of vitamin D receptor (VDR) were implicated in urolithiasis susceptibility in several case-control studies. However, these studies so far have provided conflicting results. In order to investigate the potential relationship, a meta-analysis was conducted. Methods: Eligible studies were retrieved via both computerized searches and review of references. The relation of VDR polymorphisms to urolithiasis was quantified on Apa I, Bsm I, Fok I and Taq I separately. Stratified analyses on regional characteristics and stone composition were also performed. Estimates of OR with 95% CI were summarized using the fixed- or random-effect models as appropriate. Results: A total of 17 studies were included in our analysis. There was no evidence showing significant associations between Apa I and Bsm I polymorphisms and urolithiasis risk in overall estimates. However, f allele and ff+Ff genotype in the dominant model of Fok I were related with an increase of urolithiasis risk. Taq I also presented with increased urolithiasis risk with t allele and tt+Tt genotype in the dominant model. Conclusion: Our meta-analysis indicated VDR polymorphisms could be potential biomarkers for urolithiasis susceptibility.

Keywords:
Vitamin D receptor, Urolithiasis, Etiology, Polymorphism, Meta-analysis
This content is only available via PDF.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.